A study of relationship between SARS-CoV-2 antibodies levels and host factors among general population in Zakho City, Iraq
Keywords:SARS-CoV-2, Antibodies, Risk Factors, Zakho City, Iraq
Objectives: The aim of this cross-sectional study is to evaluate the seroprevalence of total antibodies to SARS-CoV-2 and associated risk factors in Zakho City, Kurdistan Region of Iraq.
Methods: This cross-sectional study was performed at Zako City, Northern, Iraq. Blood samples were collected from different districts of Zakho city between January and March 2021. Immunoassays were performed to detect the total antibodies against SARS-CoV-2, and the associations between several variables were investigated.
Results: A total of 315 participants were agreed and enrolled in the study. The average age of the participants was 32.87±13.25 years. Among the participants, 214/315 (67.93%) were found to have antibodies against SARS-CoV-2. Among those who had positive antibodies, 169/214 (78.97%) were asymptomatic and 45/214 (21.03%) had a history of COVID-19 related symptoms. The most common symptom was fever (95.56%), followed by loss of smell (84.44%) and myalgia (80.0%). We found that antibody levels significantly associated with age (P=0.021). The presence of symptoms was significantly higher among subjects with a history of comorbidity diseases (P=0.038), and older people (P = 0.015). A significant association was found between antibody levels and the marital status (P=0.014), chronic diseases (P=0.001), presence (P=0.015) and duration of symptoms (P=0.028).
Conclusion: A significant association between antibody levels to SARS-CoV-2 and age, chronic diseases, presence and duration of symptoms were found in this study. Seroprevalence studies of antibodies to SARS-CoV-2 among general population are of utmost importance to develop infection prevention programs in our society.
Zhu, N., et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020. 382(8): p. 727-733.
Saleem, Z.S.M., Severity of Covid-19 infection among kidney transplant recipients in Duhok city, Kurdistan region, Iraq. Journal of Contemporary Medical Sciences, 2022. 8(1).
Hussein, N.R., I.A. Naqid, and Z.S.M. Saleem, A Retrospective Descriptive Study Characterizing Coronavirus Disease Epidemiology among People in the Kurdistan Region, Iraq. Mediterr J Hematol Infect Dis, 2020. 12(1): p. e2020061.
Hussein, N.R., et al., Home management scheme for patients with severe covid-19 in Duhok city, Kurdistan region of Iraq: a possible role for family physicians. Journal of Family Medicine and Primary Care, 2021. 10(11).
Ren, X., Zhou, J., Guo, J. et al. Reinfection in patients with COVID-19: a systematic review. glob health res policy 7, 12 (2022).
Hussein, N.R., et al., The First Case of COVID-19 Reinfection in Duhok City, Kurdistan Region of Iraq: A Case Report. J Kermanshah Univ Med Sci, 2020. 24(4): p. e111454.
Mousavi, M., et al., Prevalence of adverse effects of COVID19 vaccines among a sample of Iranian healthcare workers; a comparison between the three available vaccines in Iran. Journal of Contemporary Medical Sciences, 2021. 7(6).
Hussein, N.R., et al., The Impact of Breaching Lockdown on the Spread of COVID-19 in Kurdistan Region, Iraq. Avicenna J Clin Microbiol Infect, 2020. 7(1): p. 34-35.
Hussein, N.R., et al., The risk of SARS-CoV-2 reinfection in Duhok city, Kurdistan region of Iraq. Mediterranean journal of hematology and infectious diseases, 2021. 13(1).
MoH., Latest Information about Coronavirus (COVID-19). https://gov.krd/coronavirus-en/dashboard/
Sgery, A.S.H., Y.M. Hadi, and A.A. Goreal, Seasonal theory of COVID-19; one-year observation. Journal of Contemporary Medical Sciences, 2021. 7(6).
Jiang, F., et al., Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med, 2020. 35(5): p. 1545-1549.
Hussein, N.R., et al., COVID-19 antibody seroprevalence in Duhok, Kurdistan Region, Iraq: A population-based study. medRxiv, 2021: p. 2021.03.23.21254169.
Dai, M., et al., Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. 2020. 10(6): p. 783-791.
Liang, W., et al., Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol, 2020. 21(3): p. 335-337.
Klein, S.L., et al., Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest, 2020. 130(11): p. 6141-6150.
Javadinia, S.A. and M. Ariamanesh, Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. 2022. 40(2): p. 115-123.
How to Cite
Copyright (c) 2022 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.